These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Treatment and follow-up of superficial bladder cancer]. Raitanen M Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168 [No Abstract] [Full Text] [Related]
3. A new staging system for transitional cell carcinoma involvement of the prostate and reconfirmation studies of intravesical therapy for superficial bladder cancer. Hudson MR J Urol; 1996 Sep; 156(3):972-4. PubMed ID: 8709376 [No Abstract] [Full Text] [Related]
4. [BCG therapy of superficial tumors of the bladder]. Prapotnich D Bull Cancer; 1998 Feb; 85(2):135-9. PubMed ID: 9752330 [TBL] [Abstract][Full Text] [Related]
10. BCG in bladder cancer--a warning. Nicol D Aust N Z J Med; 1995 Aug; 25(4):275-7. PubMed ID: 8540864 [No Abstract] [Full Text] [Related]
11. Intravesical adjuvant treatment in superficial bladder cancer. A review of the question after 15 years of experience with the EORTC GU group. Bouffioux C Scand J Urol Nephrol Suppl; 1991; 138():167-77. PubMed ID: 1838428 [No Abstract] [Full Text] [Related]
12. Re: Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder. Herr HW J Urol; 1987 Aug; 138(2):409-10. PubMed ID: 3599266 [No Abstract] [Full Text] [Related]
13. BCG for bladder cancer. Med Lett Drugs Ther; 1991 Apr; 33(841):29-30. PubMed ID: 2002783 [No Abstract] [Full Text] [Related]
14. [Diagnosis of and therapy for non-muscle-invasive bladder cancer - state of the art]. Kausch von Schmeling I Aktuelle Urol; 2010 Sep; 41(5):307-15. PubMed ID: 20824576 [TBL] [Abstract][Full Text] [Related]
15. Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview. Witjes JA; vd Meijden AP; Debruyne FM Urol Int; 1990; 45(3):129-36. PubMed ID: 2190404 [TBL] [Abstract][Full Text] [Related]
16. The treatment of Ta-T1 bladder cancer in the era of worldwide BCG shortage. Brausi M; Morselli S Minerva Urol Nefrol; 2016 Apr; 68(2):192-3. PubMed ID: 26982374 [No Abstract] [Full Text] [Related]
17. [Pitfalls in intravesical immunotherapy of superficial carcinoma of the gallbladder with BCG vaccine]. Pacík D; Vít V; Turjanica M Rozhl Chir; 1997 Jan; 76(1):3-5. PubMed ID: 9182342 [TBL] [Abstract][Full Text] [Related]
18. The management of stage T1 grade 3 transitional cell carcinoma of the bladder. Evans CP; Busby JE BJU Int; 2003 Sep; 92(4):345-8. PubMed ID: 12930415 [No Abstract] [Full Text] [Related]
19. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder. Pham HT; Soloway MS Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909 [TBL] [Abstract][Full Text] [Related]
20. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer. Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662 [No Abstract] [Full Text] [Related] [Next] [New Search]